Dermata Therapeutics, LLC Announces Positive Top-line Results from their Phase 1 Pharmacokinetic Study of DMT210 in Acne Rosacea Patients. Click here to see Dermata's Press release. DMT210 is an IPC molecule (SIG990) that Signum licensed to Dermata to develop as a treatment for Rosacea.

"The safety results are supported with the findings from our pre-clinical data that DMT210 has a favorable safety profile, which remains extremely important to patients and dermatologists for dermal products," states Gerald Proehl, President and CEO of Dermata. "We are also very excited to see that DMT210 reduced erythema and lesion counts in only a 28-day study, giving us further confidence that we will see even greater reductions in our 90-day study."

We have partnered with Dermata Therapeutics, LLC , a private specialty pharmaceutical company developing innovative prescription drugs for dermatological conditions. We have out-Licensed SIG990 to Dermata Therapeutics for the topical treatment of rosacea. SIG990 is a novel, first-in-class anti-inflammatory compound which has the potential to both reduce erythema and decrease the papules and pustules associated with the disease. The Investigational New Drug (IND) application for SIG990 has been cleared by the U.S. Food and Drug Administration (FDA) and SIG990 is thus ready to be evaluated in subjects. Dermata has obtained an exclusive worldwide license to SIG990 and is responsible for the clinical development of the product.

With the completion of this study, Dermata plans to move into two Phase 2 studies in Acne Rosacea and Atopic Dermatitis, both expected to start later this year.

Here is a link to learn more about SIG990.

Signum Dermalogix's Pipeline